Everett Harris & Co. CA Purchases Shares of 6,602 Moderna, Inc. (NASDAQ:MRNA)

Everett Harris & Co. CA acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,602 shares of the company’s stock, valued at approximately $275,000.

Other hedge funds have also made changes to their positions in the company. State Street Corp raised its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP increased its position in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the period. Two Sigma Advisers LP purchased a new stake in Moderna during the 3rd quarter valued at approximately $23,825,000. International Assets Investment Management LLC lifted its position in Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after acquiring an additional 316,552 shares during the period. Finally, Douglas Lane & Associates LLC grew its stake in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

MRNA opened at $39.42 on Friday. The company has a market capitalization of $15.17 billion, a P/E ratio of -6.77 and a beta of 1.60. The company has a 50-day moving average of $40.89 and a 200-day moving average of $60.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a 1-year low of $31.94 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the company earned ($1.39) earnings per share. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -9.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRNA. UBS Group cut their price objective on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Sanford C. Bernstein began coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Finally, Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $67.26.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.